Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 16, 2023

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

Business Wire October 16, 2023

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

Business Wire October 10, 2023

Athersys Licenses its Animal Health Assets to Ardent Animal Health

Business Wire October 3, 2023

Athersys Director Jane Wasman Appointed Board Chair

Business Wire October 2, 2023

Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation

Business Wire September 6, 2023

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

Business Wire August 17, 2023

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Business Wire August 16, 2023

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

Business Wire August 11, 2023

Athersys to Host Business Update Conference Call on August 9th

Business Wire July 31, 2023

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma

Business Wire June 1, 2023

Athersys Restructures Debt with Supplier

Business Wire May 23, 2023

Athersys Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 18, 2023

Athersys to Participate in Three Upcoming Conferences

Business Wire May 8, 2023

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

Business Wire May 1, 2023

Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

Business Wire April 21, 2023

Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

Business Wire April 19, 2023

Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

Business Wire April 18, 2023

Athersys to Host Business Update Conference Call on April 20th

Business Wire April 10, 2023

Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Business Wire March 31, 2023